Lightchain Capital

Recent News

wugen-logo-400
June 29, 2021

Cell-based immunotherapy shows promise against melanoma

READ MORE
C4-logo-400
June 21, 2021

C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

READ MORE
C4-logo-400
June 21, 2021

C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma

READ MORE
C4-logo-400
June 16, 2021

C4 Therapeutics Announces Pricing of Public Offering

READ MORE
C4-logo-400
June 14, 2021

C4 Therapeutics Launches Proposed Public Offering

READ MORE
C4-logo-400
June 14, 2021

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies

READ MORE
CareVet-Logo-New
June 08, 2021

CareVet Launches Comprehensive Learning Institute

READ MORE
C4-logo-400
June 07, 2021

C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation

READ MORE
C4-logo-400
May 26, 2021

C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies

READ MORE

Contact Us

Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131

 

LinkedIn

Submit

©2024 LIGHTCHAIN CAPITAL, LLC  All Rights Reserved | Privacy Policy
Website by Tidal Media Group